LOL, just look at the revenue they reported last year and the year before from their Specials program. Less than $2M in each year. Probably a dozen patients or less each year. And that too after all the data they accumulated in GBM over the years including completing and publishing results of a ph 3 trial.
Where is the publication and extensive data from diverse tumor patients (outside GBM and brain tumors)? Name 10 clinicians in the US who have treated solid tumors with NWBO’s technology and still would put their neck out and suggest a $200k therapy to their patients with limited to no data (non GBM and brain)
Market Data 
Markets 
